Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single and multiple ascending dose study of oral BMS-986278 in healthy adults
NL-OMON46573Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability of single and multiple ascending oral doses of BMS-986278. Started Feb 2018; status: active, not recruiting.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON46573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46573.